TO THE EDITOR
The article entitled “Effect of Tumor Necrosis Factor-Alpha (TNF-α) on Erythropoietin- and Erythropoietin Receptor-Induced Erythroid Progenitor Cell Proliferation in β-Thalassemia/Hemoglobin E Patients”, written by Tanyong et al. [1] and published in a recent issue of your journal, was quite interesting. Here we would like to emphasize some relevant points.
Splenectomy can increase the release of TNF-α and cell apoptosis in experimental and clinical studies in different diseases [2,3,4].
Increased serum TNF-α was reported in E/b-Thal patients, particularly after splenectomy [3,4]. In sickle cell disease presenting with functional asplenia, increased amounts of TNF-α, indicative of monocyte activation, and increased serum C-reactive protein levels were reported [5].
Banyatsuppasin et al. suggested the role of the spleen in controlling mononuclear phagocytic activity in E/b-Thal patients [6]. TNF-α play roles as an inducer and effector of monocyte activation [6]. Additionally, TNF-α returned to normal after 12, 6, and 3 months of deferiprone treatment [7]. Therefore, chelation treatment can affect apoptosis independently of splenectomy. It might be important to know the effect of chelation treatment and splenectomy on tumor necrosis factor in the study of Tanyong et al. [1] based on all these investigations stated above [2,3,4,5,6,7].
Footnotes
Conflict of Interest: The author of this paper has no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
References
- 1.Tanyong D, Panichob P, Kheansaard W, Fucharoen S. Effect of tumor necrosis factor-alpha on erythropoietin- and erythropoietin receptor-induced erythroid progenitor cell proliferation in β-thalassemia/hemoglobin E patients. Turk J Hematol. 2015;32:304–310. doi: 10.4274/tjh.2014.0079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Hiroyoshi T, Tsuchida M, Uchiyama K, Fujikawa K, Komatsu T, Kanaoka Y, Matsuyama H. Splenectomy protects the kidneys against ischemic reperfusion injury in the rat. Transpl Immunol. 2012;27:8–11. doi: 10.1016/j.trim.2012.03.005. [DOI] [PubMed] [Google Scholar]
- 3.Chuncharunee S, Archararit N, Hathirat P, Udomsubpayakul U, Atichartakarn V. Levels of serum interleukin-6 and tumor necrosis factor-a in postsplenectomized thalassemic patients. J Med Assoc Thai. 1997;80(Suppl 1):S86–S91. [PubMed] [Google Scholar]
- 4.Wanachiwanawin W, Wiener E, Siripanyaphinyo U, Chinprasertsuk S, Mawas F, Fucharoen S, Wickramasinghe S, Pootrakul P, Visudhiphan S. Serum levels of tumor necrosis factor-α, interleukin-1, and interferon-γ in β0-thalassemia/HbE and their clinical significance. J Interferon Cytokine Res. 1999;19:105–111. doi: 10.1089/107999099314243. [DOI] [PubMed] [Google Scholar]
- 5.Belcher JD, Marker PH, Weber JP, Hebbel RP. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96:2451–2459. [PubMed] [Google Scholar]
- 6.Banyatsuppasin W, Butthep P, Atichartakarn V, Thakkinstian A, Archararit N, Pattanapanyasat K, Chuncharunee S. Activation of mononuclear phagocytes and its relationship to asplenia and phosphatidylserine exposing red blood cells in hemoglobin E/β-thalassemia patients. Am J Hematol. 2011;86:89–92. doi: 10.1002/ajh.21884. [DOI] [PubMed] [Google Scholar]
- 7.Del Vecchio GC, Schettini F, Piacente L, De Santis A, Giordano P, De Mattia D. Effects of deferiprone on immune status and cytokine pattern in thalassaemia major. Acta Haematol. 2002;108:144–149. doi: 10.1159/000064705. [DOI] [PubMed] [Google Scholar]